634 related articles for article (PubMed ID: 28574618)
41. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
42. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Hundsberger T; Rösler KM; Findling O
J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
[TBL] [Abstract][Full Text] [Related]
43. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
44. Quantification of muscle pathology in infantile Pompe disease.
Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
[TBL] [Abstract][Full Text] [Related]
45. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
Winkler M; von Landenberg C; Kuchenbecker K; Reimann J; Kornblum C
Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
[TBL] [Abstract][Full Text] [Related]
46. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
47. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
[TBL] [Abstract][Full Text] [Related]
48. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
[TBL] [Abstract][Full Text] [Related]
49. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
50. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
[TBL] [Abstract][Full Text] [Related]
51. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Park JS; Kim HG; Shin JH; Choi YC; Kim DS
Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
[TBL] [Abstract][Full Text] [Related]
52. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
[TBL] [Abstract][Full Text] [Related]
53. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
[TBL] [Abstract][Full Text] [Related]
54. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300
[TBL] [Abstract][Full Text] [Related]
56. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
[TBL] [Abstract][Full Text] [Related]
57. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L; Hogrel JY; Perniconi B; Kruijshaar ME; Rizopoulos D; Taouagh N; Canal A; Brusse E; van Doorn PA; van der Ploeg AT; Laforêt P; van der Beek NAME
Neurology; 2019 Nov; 93(19):e1756-e1767. PubMed ID: 31619483
[TBL] [Abstract][Full Text] [Related]
58. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
59. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]